• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

    3/26/25 4:05:00 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DRRX alert in real time by email

    Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025

    Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH)

    Webcast of earnings call today, March 26 at 4:30 p.m. ET

    CUPERTINO, Calif., March 26, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update.

    www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer." alt="DURECT Corporation (www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer.">

    "We recently achieved significant accomplishments that reinforced our plans for continuing development of larsucosterol for AH and strengthened our balance sheet," stated James E. Brown, D.V.M., President and CEO of DURECT.  "We are excited that NEJM Evidence published the results of our Phase 2b AHFIRM trial in January 2025.  Publication in such a highly regarded, peer reviewed journal provides additional validation of the potential value of larsucosterol as a treatment for AH.  We have incorporated these results, together with the additional AHFIRM data presented at The Liver Meeting 2024, into our planned Phase 3 trial design.  Additionally, in the fourth quarter we completed the sale of the ALZET product line and used the proceeds to repay the entirety of our term loan.  By strengthening our balance sheet, this transaction furthers our strategic goal of advancing development of larsucosterol for AH.  Our primary focus continues to be initiating the Phase 3 trial of larsucosterol for severe AH, contingent on securing sufficient funding.  We are engaged in active dialogue to explore all options for funding the continued development of larsucosterol, including potential business development and financing transactions."

    Recent business highlights and updates:

    • DURECT is planning a registrational Phase 3 trial to evaluate the safety and efficacy of larsucosterol for the treatment of patients with severe AH. The trial will be a randomized, double-blind, placebo-controlled, multi-center study conducted in the U.S. The primary endpoint will be 90-day survival. The trial design incorporates feedback received from the U.S. Food and Drug Administration (FDA) during a Type B meeting that took place in 2024 under Breakthrough Therapy Designation (BTD) as well as learnings from the prior Phase 2b AHFIRM trial in AH. DURECT's goal is to begin the trial in 2025, subject to obtaining sufficient funding, with topline results expected within two years of trial initiation.
    • Results from the AHFIRM Phase 2b trial were published in NEJM Evidence in January 2025. In addition to highlighting the key findings from this study, the article also included new trial data, including subgroup analyses that explain regional differences in patient populations and in AH treatment regimens. Variations in time from hospitalization to first dose highlighted the importance of timely treatment in patients with severe AH. The full article can be accessed here. Top line data from AHFIRM were previously announced in November 2023.
    • DURECT delivered an oral and two poster presentations at The Liver Meeting 2024, organized by the American Association for the Study of Liver Diseases (AASLD), in November 2024, in San Diego, California. These presentations showcased additional data from the Phase 2b AHFIRM trial. The data further support the design of the Company's planned Phase 3 trial of larsucosterol, including the importance of timely treatment in driving clinical outcomes.
    • In November 2024, DURECT sold its ALZET® line of osmotic pumps to Lafayette Instrument Co. (LIC), a portfolio company of Branford Castle Partners II, L.P., a North-American focused private equity firm. DURECT received $17.5 million from LIC. Simultaneous with this transaction, DURECT paid off all remaining obligations under its term loan agreement with Oxford Finance LLC. As a result of the sale, the operating results from our ALZET product line have been excluded from continuing operations and presented as discontinued operations in the accompanying Condensed Statements of Operations and Comprehensive Income (Loss) and Condensed Balance Sheets for all periods presented.

    Financial Highlights for the Fourth Quarter and Full Year 2024:

    • Total revenues were $0.5 million and net income was $7.8 million for the three months ended December 31, 2024 compared to total revenues of $0.9 million and net loss of $1.4 million for the three months ended December 31, 2023. Total revenues were $2.0 million and net loss was $7.9 million for the full year ended December 31, 2024, compared to total revenues of $2.6 million and net loss of $27.6 million for the full year ended December 31, 2023.
    • As of December 31, 2024, cash, cash equivalents and investments were $12.0 million, compared to cash, cash equivalents and investments of $29.8 million at December 31, 2023.

    Earnings Conference Call:

    We will host a conference call and webcast today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the Fourth Quarter and Full Year 2024 results and provide a corporate update:

    Toll Free:

    1-877-407-0784 

    International:

    1-201-689-8560

    Call Me:

    https://callme.viavid.com/viavid/?callme=true&passcode=13740526&h=true&info=company-email&r=true&B=6

    Participants can use guest dial-in numbers above to reach an operator or they can click the Call meTM link for instant telephone access to the event (dial-out). The Call meTM link will be made active 15 minutes prior to the scheduled start time.

    Webcast:

     https://viavid.webcasts.com/starthere.jsp?ei=1709648&tp_key=7b0e755edd

    The live audio webcast of the presentation will be also available on DURECT's homepage at www.durect.com on the "Events" page, under the "Investors" section.  If you are unable to participate during the live webcast, the call will be archived on DURECT's website under the same section, following the completion of the call.

    About the AHFIRM Trial

    AHFIRM was a Phase 2b randomized, double-blind, placebo-controlled, international, multi-center study conducted in subjects with severe alcohol-associated hepatitis (AH) to evaluate the saFety and effIcacy of laRsucosterol treatMent (AHFIRM). The study was comprised of three arms and enrolled 307 patients, with approximately 100 patients in each arm: (1) Placebo, which consisted of standard of care, with or without methylprednisolone capsules at the investigators' discretion; (2) larsucosterol (30 mg); and (3) larsucosterol (90 mg). Patients in the larsucosterol arms received the same supportive care without steroids. The primary outcome measure was the 90-day incidence of mortality or liver transplantation for patients treated with larsucosterol compared to those treated with placebo, and the key secondary endpoint was 90-day survival. The Company enrolled patients at clinical trial sites across the U.S., EU, U.K., and Australia. In November 2023, the Company announced topline data for the AHFIRM Trial. Reflecting the life-threatening nature of AH and the lack of therapeutic options, the U.S. FDA has granted larsucosterol Fast Track Designation and Breakthrough Therapy Designation for the treatment of AH. For more information, refer to ClinicalTrials.gov Identifier: NCT04563026.

    About Alcohol-associated Hepatitis (AH)

    AH is an acute form of alcohol-associated liver disease (ALD) associated with long-term heavy alcohol intake, often following a recent period of increased consumption (i.e., a binge). AH is typically characterized by severe inflammation and liver cell damage, potentially leading to life-threatening complications including liver failure, acute kidney injury and multi-organ failure. There are no FDA approved therapies for AH, and a retrospective analysis of 77 studies published between 1971 and 2016, which included data from 8,184 patients, showed the overall mortality from AH was 26% at 28 days, 29% at 90 days and 44% at 180 days. A subsequent global study published in December 2021, which included 85 tertiary centers in 11 countries across 3 continents, prospectively enrolled 2,581 AH patients with a median Model of End-Stage Liver Disease (MELD) score of 23.5, reported mortality at 28 and 90 days of approximately 20% and 31%, respectively. Stopping alcohol consumption is necessary, but frequently not sufficient for recovery in many moderate (defined as MELD scores of 11-20) and severe (defined as MELD scores >20) patients, and therapies that reduce liver inflammation, such as corticosteroids, are limited by contraindications, have not been shown to improve survival at 90 days or one year, and have demonstrated an increased risk of infection. While liver transplantation is becoming more common for ALD patients, including AH patients, the total number of such transplants is relatively small, and limited by organ availability. Average charges for a liver transplant exceed $875,000, and patients require lifelong immunosuppressive therapy to prevent organ rejection.

    About Larsucosterol

    Larsucosterol is an endogenous sulfated oxysterol and an epigenetic modulator. Epigenetic regulators are compounds that regulate patterns of gene expression without modifying the DNA sequence. DNA hypermethylation, an example of epigenetic dysregulation, results in transcriptomic reprogramming and cellular dysfunction, and has been reported in many acute (e.g., AH) and chronic diseases (e.g., MASH). As an inhibitor of DNA methyltransferases (DNMT1, DNMT3a and 3b), larsucosterol inhibits DNA methylation, which subsequently modulates expression of genes that are involved in cell signaling pathways associated with stress responses, cell death and survival, and lipid biosynthesis. This may ultimately lead to improved cell survival, reduced inflammation, and decreased lipotoxicity. As an epigenetic modulator, the proposed mechanism of action provides further scientific rationale for developing larsucosterol for the treatment of acute organ injury and certain chronic diseases.

    About DURECT Corporation

    DURECT is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury. Larsucosterol, DURECT's lead drug candidate, binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients. Larsucosterol is in clinical development for the potential treatment of AH, for which the FDA has granted a Fast Track and a Breakthrough Therapy designation; MASH has also been explored. For more information about DURECT, please visit www.durect.com and follow us on X (formerly Twitter) at https://x.com/DURECTCorp.

    DURECT Forward-Looking Statements

    This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, relating to: our plans to conduct a Phase 3 clinical trial of larsucosterol, the ability of the Phase 3 trial to be successful and, if successful, to support a New Drug Application filing, the sufficiency of our capital requirements (including our sale of the our ALZET product line) to further our strategic goal and our ability to secure sufficient funding for a Phase 3 trial of larsucosterol, our expectations for timing of topline results from a Phase trial of larsucosterol and the potential uses of larsucosterol to treat patients with AH and potentially other indications. Actual results may differ materially from those contained in the forward-looking statements contained in this press release, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties that could cause actual results to differ from those projected include, among other things, the risk that future clinical trials of larsucosterol are delayed or do not confirm the results from subset analyses of the AHFIRM trial, including geographic or other segmentation, or of earlier clinical or pre-clinical trials, or do not demonstrate the safety or efficacy of larsucosterol in a statistically significant manner; the risk that we do not raise sufficient capital to commence or complete the Phase 3 clinical trial of larsucosterol in patients with AH or continue to fund our operations, the risk that the FDA or other government agencies may require additional clinical trials for larsucosterol before approving larsucosterol for the treatment of AH, the risk that Breakthrough Therapy designation does not expedite the process for FDA approval and that larsucosterol may never be approved; and risks related to the sufficiency of our cash resources, our anticipated capital requirements, our ability to regain the minimum bid price for continued listing on Nasdaq, and our ability to continue to operate as a going concern. Further information regarding these and other risks is included in DURECT's most recent Securities and Exchange Commission filings, including its annual report on Form 10-K for the year ended December 31, 2024, when filed, and quarterly report on Form 10-Q for the quarter ended September 30, 2024, under the heading "Risk Factors." These reports are available on our website www.durect.com under the "Investors" tab and on the SEC's website at www.sec.gov. All information provided in this press release is based on information available to DURECT as of the date hereof, and DURECT assumes no obligation to update this information as a result of future events or developments, except as required by law.

    NOTE: Larsucosterol is an investigational drug candidate under development and has not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities for any indication.

     







    DURECT CORPORATION







    CONDENSED BALANCE SHEETS







    (in thousands)



















    As of



    As of







    December 31, 2024



    December 31, 2023 (1)







    (unaudited)







    ASSETS











    Current assets:











        Cash and cash equivalents



    $                              11,011



    $                              28,400



        Short-term Investments



    792



    1,280



        Accounts receivable, net



    453



    618



        Inventories, net



    106



    132



        Prepaid expenses and other current assets



    813



    1,465



        Discontinued operations - current assets



    -



    2,777



    Total current assets



    13,175



    34,672















    Property and equipment, net



    41



    88



    Operating lease right-of-use assets



    2,135



    3,079



    Goodwill



    2,725



    6,169



    Long-term restricted Investments



    150



    150



    Other long-term assets



    123



    123



    Discontinued operations - non-current assets



    -



    908



    Total assets



    $                              18,349



    $                              45,189















    LIABILITIES AND STOCKHOLDERS' EQUITY











    Current liabilities:











        Accounts payable



    $                                  309



    $                               1,723



        Accrued liabilities



    4,321



    5,810



        Term loan, current portion, net



    -



    16,663



        Operating lease liabilities, current portion



    1,082



    1,171



        Warrant liabilities



    1,548



    1,224



        Discontinued operations - current liabilities



    -



    420



    Total current liabilities



    7,260



    27,011















    Operating lease liabilities, noncurrent portion



    1,124



    1,967



    Other long-term liabilities



    384



    594



    Discontinued operations - non-current liabilities



    -



    834















    Stockholders' equity



    9,581



    14,783



    Total liabilities and stockholders' equity 



    $                              18,349



    $                              45,189



























    (1)  Derived from audited financial statements.









     

    DURECT CORPORATION

    CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

    (in thousands, except per share amounts)

    (unaudited)



























    Three months ended



    Twelve months ended







     December 31 



     December 31 







    2024



    2023



    2024



    2023





















    Collaborative research and development and other revenue

    $              425



    $              620



    $           1,896



    $           2,277

    Product revenue, net



    28



    274



    135



    313



    Total revenues



    453



    894



    2,031



    2,590





















    Operating expenses:



















    Cost of product revenues 

    22



    238



    78



    268



    Research and development

    1,853



    5,615



    10,383



    29,351



    Selling, general and administrative 

    1,993



    2,220



    10,032



    12,653

    Total operating expenses

    3,868



    8,073



    20,493



    42,272





















    Loss from operations



    (3,415)



    (7,179)



    (18,462)



    (39,682)





















    Other income (expense):

















    Interest and other income

    111



    449



    821



    2,129



    Change in fair value of warrant liabilities

    1,589



    4,982



    (323)



    13,583



    Issuance cost for warrants

    -



    -



    -



    (1,627)



    Loss on issuance of warrants

    -



    -



    -



    (2,033)

    Other income (expense), net

    1,700



    5,431



    498



    12,052





















    Loss from continuing operations

    (1,715)



    (1,748)



    (17,964)



    (27,630)

    Income from discontinued operations 

    9,469



    307



    10,090



    6

    Net income (loss)



    $           7,754



    $          (1,441)



    $          (7,874)



    $        (27,624)





















    Net change in unrealized gain (loss) on available-for-sale securities, net of reclassification adjustments and taxes

    $                (1)



    $                (2)



    $                13



    $                (1)





















    Total comprehensive income (loss)

    $           7,753



    $          (1,443)



    $          (7,861)



    $        (27,625)





















    Net loss per share, basic

















    Loss from continuing operations

    $           (0.06)



    $           (0.06)



    $           (0.58)



    $           (1.05)



    Income from discontinued operations

    $             0.31



    $             0.01



    $             0.33



    $                -



    Net income (loss) per common share

    $             0.25



    $           (0.05)



    $           (0.25)



    $           (1.05)





















    Net loss per share, diluted

















    Loss from continuing operations

    $           (0.06)



    $           (0.11)



    $           (0.58)



    $           (1.20)



    Income from discontinued operations

    $             0.30



    $             0.01



    $             0.33



    $                -



    Net income (loss) per common share

    $             0.24



    $           (0.10)



    $           (0.25)



    $           (1.20)





















    Weighted-average shares used in computing net income (loss) per share

















    Basic



    31,041



    29,464



    30,940



    26,256



    Diluted



    31,366



    30,046



    30,940



    26,520

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/durect-corporation-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-business-update-302412442.html

    SOURCE DURECT Corporation

    Get the next $DRRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DRRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DRRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Durect with a new price target

      HC Wainwright & Co. reiterated coverage of Durect with a rating of Buy and set a new price target of $6.00

      5/5/21 6:31:29 AM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital reiterated coverage on Durect with a new price target

      Chardan Capital reiterated coverage of Durect with a rating of Buy and set a new price target of $8.00 from $7.00 previously

      2/3/21 8:15:53 AM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for POSIMIR

      Submission status for DURECT CORP's drug POSIMIR (ORIG-1) with active ingredient BUPIVACAINE has changed to 'Approval' on 02/01/2021. Application Category: NDA, Application Number: 204803, Application Classification: Type 3 - New Dosage Form

      2/2/21 7:24:30 AM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    Financials

    Live finance-specific insights

    See more
    • DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif., March 26, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that t

      3/26/25 4:05:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update

      CUPERTINO, Calif., March 19, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its fourth quarter and full year 2024 financial results on Wednesday, March 26, 2025. Management will also host a conference call and webcast with investors to discuss the results and provide a business update at 4:30 pm Eastern Time. Details for the call are as follows:

      3/19/25 4:30:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update

      -     Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation -     Webcast of Earnings Call Today, November 13 at 4:30 p.m. ET CUPERTINO, Calif., Nov. 13, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the three months ended September 30, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute o

      11/13/24 4:01:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

      Planning a registrational Phase 3 trial for larsucosterol in alcohol-associated hepatitis (AH) with topline results expected within two years of trial initiation Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 CUPERTINO, Calif., May 13, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the first quarter ended March 31, 2025 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and l

      5/13/25 4:05:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif., March 26, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that t

      3/26/25 4:05:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update

      CUPERTINO, Calif., March 19, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its fourth quarter and full year 2024 financial results on Wednesday, March 26, 2025. Management will also host a conference call and webcast with investors to discuss the results and provide a business update at 4:30 pm Eastern Time. Details for the call are as follows:

      3/19/25 4:30:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    SEC Filings

    See more
    • SEC Form 10-Q filed by DURECT Corporation

      10-Q - DURECT CORP (0001082038) (Filer)

      5/14/25 4:05:35 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - DURECT CORP (0001082038) (Filer)

      5/13/25 4:15:17 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by DURECT Corporation

      10-K - DURECT CORP (0001082038) (Filer)

      3/27/25 5:26:22 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Sussman Norman

      4 - DURECT CORP (0001082038) (Issuer)

      10/16/24 4:47:15 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Papp Timothy M.

      4 - DURECT CORP (0001082038) (Issuer)

      10/16/24 4:46:24 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President & CEO Brown James E

      4 - DURECT CORP (0001082038) (Issuer)

      10/16/24 4:42:29 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    Leadership Updates

    Live Leadership Updates

    See more
    • KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

      KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next

      9/4/24 8:00:00 AM ET
      $AVTX
      $DRRX
      $HALO
      $MESO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Medicinal Chemicals and Botanical Products
    • DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board

      CUPERTINO, Calif., March 21, 2023 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023.  Ms. Maderis succeeds David Hoffmann as Chair of the Board. Mr. Hoffman has decided not to stand for re-election and will retire from the board on June 21, 2023 when his current term as a board member expires.    "We thank Dave for his many years of service on the DURECT Board and wish him well," stated James E. Brown, D.V.M., President and CEO of DURECT.  "Gail is a seasoned biopharmaceutical executive and we have benefitted from her innovative and strategic thinking as a board member since January

      3/21/23 4:30:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer

      CUPERTINO, Calif., July 5, 2022 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a biopharmaceutical company focused on epigenetic regulation to develop treatments for acute organ injury and chronic liver diseases, today announced the appointment of Timothy M. Papp as its Chief Financial Officer. In this new role, Mr. Papp will direct and oversee all financial and capital markets activities including accounting, financial reporting, financial planning and analysis, financial strategy, and investor relations. "We are excited to welcome Tim to our executive leadership team, as he brings his deep understanding of corporate finance and corporate value drivers to DURECT," stated James E. Brown,

      7/5/22 8:30:00 AM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by DURECT Corporation

      SC 13G/A - DURECT CORP (0001082038) (Subject)

      11/19/24 5:10:25 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by DURECT Corporation

      SC 13G - DURECT CORP (0001082038) (Subject)

      3/27/24 3:15:14 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by DURECT Corporation

      SC 13G - DURECT CORP (0001082038) (Subject)

      2/16/24 4:09:22 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care